Stuttgart, Univ., Diss., 2008.

Freiburg i. Br., Univ., Diss., 2008.

Freie Universiẗat, Diss., 2005--Zugl. : Berlin. / Dateiformat: zip, Dateien im PDF-Format. Erscheinungsjahr an der Haupttitelstelle: 2005.

Orientadores: Edi Lucia Sartorato, Andrea Trevas Maciel-Guerra / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-15T16:54:52Z (GMT). No. of bitstreams: 1 Miranda_PauloMauriciodoAmorDivino_M.pdf: 2620124 bytes, checksum: aacc629866a9ff7880f48f266f4f3743 (MD5) Previous issue date: 2010 / Resumo: Nos seres humanos, a visão é o sentido que retrata com melhor fidelidade o ambiente que os cerca. A ausência do sentido da visão é definida como cegueira. As conseqüências da cegueira são problemas de saúde pública importantes, pois têm um impacto significativamente negativo sobre o desenvolvimento econômico e social dos indivíduos afetados. A perda visual pode ser resultado de lesão nos centros nervosos superiores, nas vias ópticas ou em estruturas do próprio olho. As causas vão desde traumas oculares até doenças congênitas, como: glaucoma congênito, catarata congênita e Neuropatia Óptica Hereditária de Leber (LHON). A LHON é uma doença, causada por alterações no DNA mitocondrial, caracterizada pela perda repentina da visão em ambos os olhos, devido a uma degeneração do nervo óptico. Atualmente, 17 principais mutações associadas à LHON foram registradas, onde três dessas mutações representam 95% dos casos (mutações primárias) e as 14 mutações subseqüentes representam apenas 5% do total (mutações secundárias). Não foram relatados, até o momento, estudos que definam a freqüência das mutações ou estudos populacionais de prevalência no Brasil. Desta forma, o presente estudo teve como principal objetivo definir a freqüência das mutações da LHON em pacientes brasileiros. Foram avaliados 55 pacientes com hipótese diagnóstica de LHON ou neuropatia óptica adquirida de origem desconhecida. Mutações primárias (G11778A, T14484C e G3460A) e mutações secundárias nos genes MT-ND1, MT-ND4, MT-ND4L, MT-ND5, MT-ND6 e MT-CYB foram rastreadas em todos os indivíduos estudados. O rastreamento das mutações primárias foi realizado pelo método de restrição enzimática. Para os pacientes que não apresentaram mutações primárias procedeu-se o seqüenciamento direto para rastrear mutações secundárias. O método de DHPLC foi padronizado para o rastreamento de mutações primárias. Mutações primárias foram encontradas em 19 pacientes, ou seja, em 38,2% dos casos. A freqüência dessas mutações ficou definida como: 67% da mutação G11778A (13 casos), 28% da mutação T14484C (5 casos) e 5% da mutação G3460A (apenas 1 caso). A mutação G11778A apresentou números próximos aos encontrados nas populações estudadas em outras partes do mundo, confirmando ser a principal causa de LHON também em pacientes brasileiros. A mutação T14484C, como na maioria das populações mundiais, mostrou-se como a segunda maior causa da LHON, porém mostrou uma freqüência quase duas vezes maior que o descrito na literatura. Enquanto que a mutação G3460A apresentou freqüência muito baixa se comparada as das demais populações estudadas. Não foram encontradas mutações secundárias. A ausência dessas mutações pode ser atribuída à possibilidade de haver mutações em regiões do DNA mitocondrial não rastreadas no presente estudo. Há também a possibilidade de os pacientes em que não foram localizadas mutações não serem portadores da LHON, apresentando outra anomalia com dados clínicos semelhantes. No presente estudo também foi possível, a partir do teste molecular a confirmação da hipótese diagnóstica de LHON em alguns pacientes / Abstract: The vision is the sense that best expresses the environment surrounding the mankind. The term blindness is used to define the absence of the vision. The consequences of blindness are important problems of public health concern as they cause a negative impact on the economic and social development of the affected individuals). The visual loss is characterized by congenital deprivation and it can be total or partial, permanent or temporary. Furthermore, visual loss may result from superior nerve centers damage, optic pathways lesions or physic damage of the eye itself. Thus, the visual loss causes range from trauma to ocular congenital diseases such as congenital glaucoma, congenital cataract and Leber Hereditary Optic Neuropathy (LHON). LHON is a mitochondrial disease characterized by sudden loss of vision in both eyes, due to an optic nerve degeneration. Currently, 17 main LHON associated mutations were published, three of which account for 95% of the cases (primary mutations) and the subsequent fourteen account for only 5% of the total (secondary mutations). The frequencies of mutations envolved in LHON in Brazilian patients have not been reported so far. Therefore, the aim of this study was to define the LHON mutations frequency in Brazilian patients. We evaluated 55 patients with LHON diagnosis or acquired optic neuropathy of unknown origin. Primary mutations (G11778A, T14484C and G3460A) and secondary mutations in the genes MT-ND1, MT-ND4, MT-ND4L, MT-ND5, MT-ND6 and MT-CYB were screened in all individuals studied. Screening of primary mutations was performed by the method of enzyme restriction. Patients who did not have primary mutations were screened for secondary mutations by direct sequencing. The DHPLC method was used for primary mutations screening. Primary mutations were found in 19 patients, ie 38.2% of cases. The frequency of these mutations was defined as 67% for the G11778A mutation (13 cases), 28% for the T14484C mutation (5 cases) and 5% for the G3460A mutation (only 1 case). The mutation G11778A showed numbers similar to those found in the populations studied in other parts of the world, confirming that the main cause of LHON also in Brazilian patients. The T14484C mutation, as in most world populations, showed up as the second leading cause of LHON, but it showed a frequency almost twice that reported. While the G3460A mutation frequency showed very low compared to the other populations studied. No secondary mutation was found. The absence of these mutations can be attributed to the possibility of mutations in mitochondrial DNA regions not screened in this study. There is also the possibility that patients in whom no mutations were not found to be carriers of LHON, with another anomaly with similar clinical data. This study evaluated the situation of primary and secondary mutations associated with LHON in a sample of Brazilian individuals. It was also possible, from the molecular testing to confirm the diagnosis of LHON in some patients / Mestrado / Genetica Animal e Evolução / Mestre em Genética e Biologia Molecular

Im Katabolismus methylverzweigter Fettsäuren spielt die alpha-Methylacyl-CoA-Racemase eine wichtige Rolle, indem sie die (R)- und (S)-Isomere von alpha-methylverzweigten Fettsäuren als Coenzym A Thioester racemisiert. Methylverzweigte Fettsäuren entstehen beim Abbau von Isoprenoiden und werden darüber hinaus auch von vielen Organismen, wie z.B. Mycobakterien, synthetisiert. Die Hauptaufgabe der Racemase ist aber vermutlich in der Biosynthese von Gallensäuren zu sehen. Das Ziel der vorliegenden Arbeit war es, die alpha-Methylacyl-CoA-Racemase aus humanem Gewebe zu reinigen und zu charakterisieren sowie ihre physiologische Rolle im Katabolismus verzweigtkettiger Fettsäuren und der Gallensäurebiosynthese zu untersuchen. Die alpha-Methylacyl-CoA-Racemase wurde aus humanem Gewebe zur Homogenität gereinigt, umfassend biochemisch charakterisiert und zur genauen molekularbiologischen Analyse in E.coli kloniert. Die Aktivität der Racemase wurde anhand der [³H]H2O-Freisetzung aus [alpha-³H]-a-Methylacyl-CoAs bestimmt. Die humane Racemase ist in der aktiven Form ein monomeres Protein und besteht aus 382 Aminosäuren. Als Substrate akzeptiert das Enzym ein breites Spektrum von alpha-Methylacyl-CoAs. Neben den Coenzym A-Thioestern alpha-methylverzweigter Fettsäuren, wie Pristansäure, werden auch CoA-Ester von Steroidderivaten, z.B. des Gallensäureintermediats Trihydroxycoprostansäure, und aromatischen Phenylpropionsäuren, wie dem Analgetikum Ibuprofen, umgesetzt. Freie Fettsäuren, geradkettige oder beta-methylverzweigte Acyl-CoAs werden nicht racemisiert. Die alpha-Methylacyl-CoA-Racemase ist im Menschen zu ca. 80 Prozent auf die Peroxisomen und ca. 20 Prozent auf die Mitochondrien verteilt, wobei entsprechende peroxisomale (PTS 1) und mitochondriale (MTS) Transportsignale die Lokalisation bestimmen. Die vollständige cDNA-Sequenz der humanen a-Methylacyl-CoA-Racemase hat eine Gesamtlänge von 2039 Basenpaaren mit einem offenen Leseraster von 89 - 1237 bp. Das Startcodon ATG ist in eine klassische Kozak-Sequenz zum Translationsstart eingebettet. Die Protein endet am C-Terminus mit dem Sequenzmotiv –KASL, das dem peroxisomalen Transportsignal (PTS I) einiger Säugetierkatalasen entspricht. Aufgrund alternativer Polyadenylierung sind in allen untersuchten menschlichen Geweben Transkripte von 1,6 kb bzw. 2,0 kb zu finden. Es liegt keine gewebsabhängige Polyadenylierung vor, die Racemase wird aber gewebsspezifisch exprimiert (besonders stark in Leber und Niere). Das humane Racemasegen liegt auf dem kurzen Arm des Chromosoms 5 nahe am Centromer (5p1.3), im Intervall von D5S651 (46,6 cM) und D5S634 (59.9 cM). / Racemization is an essential step for bile acid synthesis and it is important for degradation of alpha-methyl branched-chain fatty acids. The (R)- and (S)-isomers of alpha-methyl-branched chain fatty acids were shown to be interconverted as coenzyme A thioesters by an alpha-methylacyl-CoA racemase. Various branched-chain fatty acids arise in the catabolism of isoprenoids and are also synthesized by a variety of organisms, particularly mycobacteria. The aim of this work was to purify and to characterize the racemase from human tissue and to analyse the physiological role in the degradation of branched-chain fatty acids and the bile acid synthesis. The alpha-methylacyl-CoA racemase was purified from human liver to apparent homogeneity. The enzyme was exhaustively characterized by methods of biochemistry and protein chemistry. The cDNA coding for human racemase was cloned in E. coli and sequenced. A radiometric assay with 2-methyl[2-³H]acyl-CoAs as substrates was used routinely for monitoring purification procedure. The active form of the enzyme is a monomeric protein comprising 382 amino acids. The enzyme accepts a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis) as substrates. Also arylpropionyl-CoAs such as the anti-inflammatory drug ibuprofen are accepted, but neither free fatty acids, beta-methyl-branched nor linear-chain acyl-CoAs. In human tissues 80 - 90 Prozent of the racemase activity is found in peroxisomes and 10 - 20 Prozent in mitochondria. Degradation of branched chain fatty acids is located in both compartments, so the enzyme has to be distributed between peroxisomes and mitochondria. No evidence was found for the existence of isoenzymes or different transcription products. It appears that only one mRNA is transcribed from one gene and that also only one protein is synthesized. The different recognition of peroxisomal (PTS 1) and mitochondrial targeting signals (MTS) may determine the subcellular distribution. The complete cDNA sequence has an overall length of 2039 base pairs, with a open reading frame between 89 - 1237 bp. The ATG start codon is embedded in a classical Kozak sequence for translation start. The C-Terminus of the protein is –KASL, which is very similar to the peroxisomal targeting signals (PTS 1) of many mammalian catalases. In all human tissues analysed in this work two different transcripts of racemase with sizes of 1,6 kb and 2,0 kb have been found and show alternate polyadenylation. Polyadenylation of racemase is not tissue-dependent but its expression is tissue-specific (strong activity is found in liver and kidney). The human racemase gene is localized on the short arm of chromosome 5, near the centromer (region 5p1.3) and between the markers D5S651 (46,6 cM) and D5S634 (59.9 cM).

Background Hedgehog signaling plays an important role in embryonic development, organogenesis and cancer. In the adult liver, Hedgehog signaling in non-parenchymal cells has been found to play a role in certain disease states such as fibrosis and cirrhosis. However, whether the Hedgehog pathway is active in mature healthy hepatocytes and is of significance to liver function are controversial. Findings Two types of mice with distinct conditional hepatic deletion of the Smoothened gene, an essential co-receptor protein of the Hedgehog pathway, were generated for investigating the role of Hedgehog signaling in mature hepatocytes. The knockout animals (KO) were inconspicuous and healthy with no changes in serum transaminases, but showed a slower weight gain. The liver was smaller, but presented a normal architecture and cellular composition. By quantitative RT-PCR the downregulation of the expression of Indian hedgehog (Ihh) and the Gli3 transcription factor could be demonstrated in healthy mature hepatocytes from these mice, whereas Patched1 was upregulated. Strong alterations in gene expression were also observed for the IGF axis. While expression of Igf1 was downregulated, that of Igfbp1 was upregulated in the livers of both genders. Corresponding changes in the serum levels of both proteins could be detected by ELISA. By activating and inhibiting the transcriptional output of Hedgehog signaling in cultured hepatocytes through siRNAs against Ptch1 and Gli3, respectively, in combination with a ChIP assay evidence was collected indicating that Igf1 expression is directly dependent on the activator function of Gli3. In contrast, the mRNA level of Igfbp1 appears to be controlled through the repressor function of Gli3, while that of Igfbp2 and Igfbp3 did not change. Interestingly, body weight of the transgenic mice correlated well with IGF-I levels in both genders and also with IGFBP-1 levels in females, whereas it did not correlate with serum growth hormone levels. Conclusions Our results demonstrate for the first time that Hedgehog signaling is active in healthy mature mouse hepatocytes and that it has considerable importance for IGF-I homeostasis in the circulation. These findings may have various implications for mouse physiology including the regulation of body weight and size, glucose homeostasis and reproductive capacity.

Universiẗat, Diss., 2006--Giessen.

Universiẗat, Diss., 2006--Giessen.

Würzburg, Univ., Diss., 2009. / Zsfassung in dt. Sprache.

Thesis (doctoral)--Katholieke Universiteit Leuven.